Holen Sie sich die Stockscreener-App
0.2874
7.28%
0.0195
Handel nachbörslich:
.29
0.0026
+0.90%
Hcw Biologics Inc Aktie (HCWB) Neueste Nachrichten
Growth Recap: Will HCW Biologics Inc outperform tech stocksEarnings Risk Report & Expert Verified Stock Movement Alerts - baoquankhu1.vn
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results - The Manila Times
HCW Biologics Q4 revenue drops sharply on license suspension - TradingView
HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
HCW Biologics (NASDAQ: HCWB) outlines immunotherapy pipeline, deals and IP - Stock Titan
HCW Biologics (NASDAQ: HCWB) 2025 loss, going concern and Nasdaq risk - Stock Titan
Hair-loss trial starts as HCW Biologics warns on funding runway - Stock Titan
HCW Biologics Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Growth Value: Is HCW Biologics Inc gaining market shareDividend Hike & Low Risk High Reward Trade Ideas - baoquankhu1.vn
HCWB Should I Buy - Intellectia AI
HCWB (HCW Biologics) PB Ratio : (As of Mar. 27, 2026) - GuruFocus
HCWB Technical Analysis & Stock Price Forecast - Intellectia AI
Forecast Cut: Will HCW Biologics Inc benefit from green energy policiesWeekly Stock Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
HCW Biologics highlights positive findings for CAR-T therapy manufacturing - MSN
HCW Biologics (HCWB) Projected to Post Earnings on Wednesday - Defense World
If You Invested $1,000 in Hcw Biologics Inc. (HCWB) - Stock Titan
HCWB stock soars pre-market on positive research results for CAR-T cell therapy - MSN
HCW Biologics receives $7M upfront fee from China licensee By Investing.com - Investing.com South Africa
HCW Biologics Grants Exclusive Worldwide License for HCW11-006 to Trimmune with $7M Upfront Payment and Future Royalties 1 - Minichart
HCW Biologics Secures $7M License Deal for HCW11-006 - TipRanks
HCW Biologics Closes Exclusive Global License for HCW11-006, Receives Upfront Payment - TradingView
HCW Biologics receives $7M upfront fee from China licensee - Investing.com
[8-K] HCW Biologics Inc. Reports Material Event - Stock Titan
HCW Biologics Inc. Receives $7 Million Upfront License Fee from Beijing Trimmune Biotech for HCW11-006 Development and Commercialization Rights - Quiver Quantitative
Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic - TradingView
New fusion immunotherapy deal brings HCW Biologics $7M upfront - Stock Titan
HCWB HCW Biologics (NASDAQ) +81% pre market 17 Mar 2026: CAR-T paper lifts volume - Meyka
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - Investing News Network
Small Cap Stocks To Keep An Eye OnMarch 16th - MarketBeat
HCW Biologics Inc. (HCWB) Stock: Science Advances Study Highlights Next-Gen CAR-T Manufacturing Strategy - parameter.io
HCW Biologics’ compound shows promise in CAR-T cell production By Investing.com - Investing.com Canada
Promising Pharmaceutical Stocks To Keep An Eye OnMarch 16th - MarketBeat
Trading Volume Surges in Biotech, Tech, and Energy Stocks | Market RecapNews and Statistics - IndexBox
HCW Biologics (HCWB) spikes 71% as micro-cap volatility returns after Nasdaq compliance and recent financing - Quiver Quantitative
HCW Biologics announces positive research results for CAR-T cell therapy - TipRanks
HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy - Asianet Newsable
HCW Biologics’ compound shows promise in CAR-T cell production - Investing.com
HCW Biologics reports positive CAR-T cell therapy research results By Investing.com - Investing.com Australia
HCW Biologics Announces Positive Research Results for CAR-T - GlobeNewswire
HCW Biologics (NASDAQ: HCWB) seeks approval for large warrant issuances and deep repricing - Stock Titan
HCW Biologics restructures obligations to regain Nasdaq compliance - MSN
Hedge Fund Moves: What is HCW Biologics Incs revenue forecastLayoff News & Low Risk Entry Point Tips - baoquankhu1.vn
AI Stocks: Will HCW Biologics Inc outperform tech stocksTrade Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
Buyout Rumor: Can HCW Biologics Inc stock double in the next yearWeekly Investment Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
AI Stocks: Is HCW Biologics Inc forming a breakout patternWeekly Gains Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
HCWB Earnings History & Surprises | EPS & Revenue Results | HCW BIOLOGICS INC (NASDAQ:HCWB) - ChartMill
HCW Biologics (NASDAQ: HCWB) seeks warrant approvals at Apr 27 meeting - Stock Titan
HCWB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight - The Globe and Mail
HCW Biologics regains compliance with all continued listing rules for Nasdaq per Nasdaq determination letter - marketscreener.com
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - The Manila Times
HCW Biologics (NASDAQ: HCWB) back in full Nasdaq compliance - Stock Titan
HCW Biologics : February 2026 - marketscreener.com
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):